Oruka Therapeutics: T. Rowe Price reports 6.6%
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Oruka Therapeutics, Inc. (ORKA) was the subject of a Schedule 13G in which T. Rowe Price Investment Management, Inc. reported an aggregate beneficial-ownership amount of 4,392,166 common shares, or 6.6% of the class, as of September 30, 2026. It reported sole voting power over 4,216,126 shares and sole dispositive power over 4,392,166 shares, with shared voting and dispositive power each reported as zero. T. Rowe Price Investment Management stated that the filing should not be construed as an admission of beneficial ownership and expressly denied beneficial ownership.
Key Figures
Key Terms
beneficial ownership technical
Sole Voting Power technical
Sole Dispositive Power technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.